Data / Drug companies / Amerisyn LLC
Amerisyn LLC: 26 products in the FDA NDC directory, labeler code 87564
Amerisyn LLC (labeler code 87564) lists 26 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 26 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 7, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 87564
- Products in commercial distribution
- 26
- Packages
- 36
- Finished drugs by generic name
- 9
- Prescription products
- 26
- Over the counter products
- 0
- Flagged as original packager
- 22 of 22 products that carry the flag
- Started marketing in the last 12 months
- 26
- Earliest marketing start
- June 30, 2026
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Terazosin hydrochloride | 8 | 15 |
| Risperidone | 5 | 43 |
| Eltrombopag olamine | 4 | 7 |
| Mexiletine hydrochloride | 3 | 16 |
| Nicardipine hydrochloride | 2 | 27 |
| Ketoconazole | 1 | 35 |
| Terbinafine hydrochloride tablet | 1 | 1 |
| Diclofenac potassium, film coated | 1 | 8 |
| Ketorolac tromethamine | 1 | 69 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 13 | 50% |
| Tablet, film coated | 5 | 19.2% |
| Tablet, orally disintegrating | 5 | 19.2% |
| Tablet | 3 | 11.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Terazosin hydrochloride | 87564-084 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 87564-083 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 87564-082 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 87564-081 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Mexiletine hydrochloride | 87564-054 | Capsule | Generic drugs (ANDA) | August 6, 2026 |
| Mexiletine hydrochloride | 87564-053 | Capsule | Generic drugs (ANDA) | August 6, 2026 |
| Mexiletine hydrochloride | 87564-052 | Capsule | Generic drugs (ANDA) | August 6, 2026 |
| Ketoconazole | 87564-051 | Tablet | Generic drugs (ANDA) | August 6, 2026 |
| Risperidone | 87564-017 | Tablet, orally disintegrating | Generic drugs (ANDA) | August 6, 2026 |
| Risperidone | 87564-016 | Tablet, orally disintegrating | Generic drugs (ANDA) | August 6, 2026 |
| Risperidone | 87564-015 | Tablet, orally disintegrating | Generic drugs (ANDA) | August 6, 2026 |
| Risperidone | 87564-014 | Tablet, orally disintegrating | Generic drugs (ANDA) | August 6, 2026 |
| Risperidone | 87564-013 | Tablet, orally disintegrating | Generic drugs (ANDA) | August 6, 2026 |
| Terbinafine | 87564-010 | Tablet | Generic drugs (ANDA) | August 3, 2026 |
| Nicardipine hydrochloride | 87564-028 | Capsule | Generic drugs (ANDA) | July 26, 2026 |
| Nicardipine hydrochloride | 87564-027 | Capsule | Generic drugs (ANDA) | July 26, 2026 |
| Ketorolac Tromethamine | 87564-018 | Tablet, film coated | Generic drugs (ANDA) | July 26, 2026 |
| Diclofenac potassium | 87564-011 | Tablet | Generic drugs (ANDA) | July 26, 2026 |
| Terazosin Hydrochloride | 87564-009 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Terazosin Hydrochloride | 87564-008 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Terazosin Hydrochloride | 87564-007 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Terazosin Hydrochloride | 87564-006 | Capsule | Generic drugs (ANDA) | July 1, 2026 |
| Eltrombopag olamine | 87564-035 | Tablet, film coated | Generic drugs (ANDA) | June 30, 2026 |
| Eltrombopag olamine | 87564-034 | Tablet, film coated | Generic drugs (ANDA) | June 30, 2026 |
| Eltrombopag olamine | 87564-033 | Tablet, film coated | Generic drugs (ANDA) | June 30, 2026 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.